BillionToOne’s stock surged 16.3% following an earnings report that impressed investors with outsized revenue growth, significant test volume expansion, and margin expansion, signaling confidence in the company’s high-growth trajectory and innovative product pipeline.

• Total revenue grew 84% year over year, driven by a 44% increase in test volume.
• Average selling prices rose 28% to $571 per test, supporting gross margin expansion to 73%, up 9 percentage points year over year.
• Cost of goods sold remained controlled at $153 per test despite a higher mix of oncology tests with typically higher COGS.
• The company reported a strong profitability profile with a 16% GAAP operating margin and 24% adjusted EBITDA margin.
• Recent market developments include the launch of Unity Confirm, a novel noninvasive fetal cell-based confirmation test addressing a critical clinical need, alongside progress on oncology product launches and network coverage expansion to 300 million U.S. lives.